Literature DB >> 4022559

Clearance of intravitreal 3H-fluorouracil.

J L Case, G A Peyman, A Barrada, R Hendricks, R Fiscella, M Hindi.   

Abstract

The clearance of intravitreally administered 5-fluorouracil (5-FU) was studied under five experimental conditions. The same nontoxic dose resulted in similar initial intravitreal concentrations and cleared rapidly from all eyes (approximately 90% clearance within eight hours). Half-life values ranged from 46 to 168 minutes. The longest half-life occurred in aphakic-vitrectomized eyes in which hyaluronic acid (Healon) was substituted for vitreous (168 minutes). A similar half-life was found in normal eyes (150 minutes). The shortest half-life occurred in aphakic-vitrectomized eyes postoperatively (46 minutes). Intermediate half-life values occurred in vitrectomized but phakic eyes postoperatively (67 minutes) and in aphakic-vitrectomized "quiet" eyes (at least two weeks postoperatively) (82 minutes).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4022559

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  5 in total

1.  Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates.

Authors:  G A Peyman; M Conway; B Khoobehi; K Soike
Journal:  Int Ophthalmol       Date:  1992-03       Impact factor: 2.031

2.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

3.  Effects of selected repeated intravitreal chemotherapeutic agents.

Authors:  J Vernot; G A Peyman; R Gailitis; R Fiscella; M Woodhouse; D Weinberg
Journal:  Int Ophthalmol       Date:  1985-11       Impact factor: 2.031

4.  Liposome-encapsulated 3H-5FU in rabbits.

Authors:  P Fishman; G A Peyman; R Hendricks; S L Hui
Journal:  Int Ophthalmol       Date:  1989-09       Impact factor: 2.031

5.  A sustained dual drug delivery system for proliferative vitreoretinopathy.

Authors:  Ying Xiao; Kyung Seek Choi; David Warther; Kristyn Huffman; Stephanie Landeros; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.